# PT-141 Side Effects in the Clinical Research: Nausea, Flushing, Blood Pressure > PT-141 side effects from the RCTs and FDA label: nausea ~40% (the leading reason for discontinuation), flushing ~21%, headache ~12%, transient blood-pressure rise, and MC1R hyperpigmentation. Cited. Nausea leads, and it leads discontinuations. The cited adverse-event profile from the trials and the label — and, fenced off from it, what the forums report. ## The short version These are the PT-141 side effects the trials actually recorded. The big one is nausea: about `40%` of women in long-term use felt it, and it was the most common reason people stopped [4]. Flushing (a warm, reddening sensation) and headache come next. The drug causes a brief, temporary rise in blood pressure with a small drop in heart rate, so it is contraindicated (must not be used) in people with uncontrolled high blood pressure or known heart disease [6]. With frequent repeated dosing, some skin and gum darkening can occur. Below, the cited clinical data come first; a clearly-labeled "field reports" box of unverified community experiences is kept separate. ## The Cited Adverse-Event Profile In the `52-week` open-label extension of RECONNECT (`684` women enrolled), the most common drug-related treatment-emergent adverse events were nausea (`40.4%`), flushing (`20.6%`), and headache (`12.0%`) [4]. No new safety signals emerged over the year, and the desire improvements were sustained — but nausea was the principal tolerability issue and a notable driver of discontinuation [4]. In the two pivotal Phase 3 trials, the same three events — nausea, flushing, and headache — were the most frequently reported, consistent with the extension data [3]. Injection-site reactions and nasal congestion are also documented in the labeling [6]. The pattern is stable across the program: a tolerability profile dominated by nausea, with vasomotor (flushing) and headache effects behind it. ## Nausea: The Leading Reason Participants Discontinued Nausea is both the most common adverse event and the leading reason participants stopped the drug [4]. At `40.4%` over 52 weeks it is not a rare event — it is the defining tolerability fact of bremelanotide [4]. Most nausea in the trials was described as mild-to-moderate and occurred around dosing, but its frequency is why it dominates any honest account. This is the single most important number on the page for a researcher weighing the literature: the efficacy is modest and the most common side effect is common. Injection timing and dose strategy have been studied as mitigations, but nausea remains the headline tolerability constraint [4]. The regimen these rates were recorded under is the [PT-141 dosage on the label](/dosage): `1.75 mg` subcutaneous, as-needed. ## The Cardiovascular Signal: A Transient Blood-Pressure Rise Bremelanotide produces a transient increase in blood pressure with a corresponding decrease in heart rate after each dose [6]. The effect is temporary and resolves, but it is real and dose-related, and it defines the drug's hardest safety boundary. The US prescribing information **contraindicates** use in people with uncontrolled hypertension or known cardiovascular disease [6]. This is not a soft caution — it is a contraindication, the strongest label restriction. Ambulatory blood-pressure substudies characterized the rise, and the labeling directs that blood pressure be considered before use [6]. For anyone reading this compound's safety record, the cardiovascular signal sits alongside nausea as a first-order fact. ## Hyperpigmentation: Focal Skin and Gum Darkening Hyperpigmentation — darkening of the skin, gums, or breasts — is reported with repeated, frequent dosing and is attributed to MC1R activation, a peripheral melanocortin receptor [6]. It is a direct consequence of the receptor family the drug acts on: MC1R drives melanin production [1]. The labeling notes focal hyperpigmentation, including of the face and gingiva, occurring more often with more frequent dosing [6]. It is the predictable cosmetic cost of a melanocortin agonist and is one of the most widely-discussed effects researchers pass around — though the verified mechanism (MC1R) is what makes it a cited finding rather than folklore. ## Liver-Safety Reference The NIH LiverTox monograph characterizes bremelanotide as a parenterally administered melanocortin receptor agonist associated with mild serum enzyme elevations and rare instances of clinically apparent acute liver injury [7]. It is metabolized by amide-bond hydrolysis with minimal drug-drug interactions [7]. This is a reference-grade safety note, not a common event — but it belongs in a complete tolerability picture. ## Field reports (not clinical data) What follows is a summary of commonly-described first-hand patterns from non-clinical sources — forums and informal discussion, not trials. It is unverified, attributed to no journal or study, and is not evidence and not advice. Researchers commonly describe a rapid-onset warm "flush" sensation within roughly the first hour; nausea that comes on within the same window and is the most-complained-about effect; a spontaneous, desire-led rather than purely physical effect; and, for those who dose frequently, the transient skin-darkening warning that gets passed around as a reason to keep frequency low. Anecdotal off-label use in men is widely discussed online. None of this is a measured outcome, none of it is a dosing protocol, and none of it should be read as a reason to self-administer. Commonly-described patterns from non-clinical sources; not measured outcomes and not a finding. --- A precision-metrology readout of the bremelanotide record — each measured value logged to its study and tagged in-spec or disputed, the effect-size debate kept beside the number it qualifies and the field reports fenced off the calibrated panel; no clinic behind the instrument and nothing here dosed, dispensed, or sold.